Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003, 24/10/2005.

Name of entity

Bud	dy Technologies Limited	
ABN 21 1	21 184 316	
We ((the entity) give ASX the following infor	mation.
	rt 1 - All issues nust complete the relevant sections (attach sheets	s if there is not enough space).
1	⁺ Class of ⁺ securities issued or to be issued	Fully Paid Ordinary Shares – Quoted
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	1,621,556 Fully Paid Ordinary Shares
3	Principal terms of the *securities (eg, if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Fully Paid Ordinary Shares - Quoted

Appendix 3B

New issue announcement

4	Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?	Yes for Ordinary Shares
	 If the additional securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 	
5	Issue price or consideration	1,621,556 Ordinary Shares on conversion of Employee Incentive Performance Rights (Nil Price)
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Ordinary shares issued on vesting and conversion of Employee Incentive Performance Rights
6а	Is the entity an ⁺ eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h in relation to the ⁺ securities the subject of this Appendix 3B, and comply with section 6i	No
6b	The date the security holder resolution under rule 7.1A was passed	-
	+ See chapter to for defined terms	

⁺ See chapter 19 for defined terms

6c	Number of *securities issued without security holder approval under rule 7.1	-
6d	Number of *securities issued with	Nil
	security holder approval under rule 7.1A	
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	-
6f	Number of securities issued under an exception in rule 7.2	1,621,556
6g	If securities issued under rule 7.1A, was	N/A
og	issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values.	
	Include the source of the VWAP calculation.	
6h	If securities were issued under rule	N/A
011	7.1A for non-cash consideration, state date on which valuation of	14//
	consideration was released to ASX Market Announcements	
. .		7. 200 (14 207
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	7.1 280,641,235 7.1A -
_		
7	Dates of entering *securities into uncertificated holdings or despatch of certificates	31 July 2019

	Number and +class of all +securities
8	quoted on ASX (including the securities
	in clause 2 if applicable)

Number	†Class
1,870,941,566	Fully Paid Ordinary Shares
	,

9 Number and +class of all +securities not quoted on ASX (including the securities in clause 2 if applicable)

Number	+Class
2,806,647	Options exercisable at \$0.10 expiring 17/11/2020
100,000,000	Options exercisable at \$0.0759 cents expiring 01/04/2024
532,765	Options exercisable at \$0.0759 cents expiring 29/03/2023
4,898,503	Performance Rights
31,833,334	Performance Shares
20,734,713	Employee Incentive Performance Rights
24,000,000	Performance Shares (LIFX)
24,000,000	Performance Rights (LIFX)

10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A			

Part 2 - Bonus issue or pro rata issue

11	Is security holder approval required?
	requirea:
12	Is the issue renounceable or non-renounceable?
13	Ratio in which the *securities will be offered

⁺ See chapter 19 for defined terms.

14	*Class of *securities to which the offer relates	
15	⁺ Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	
18	Names of countries in which the entity has *security holders who will not be sent new issue documents	
	Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	
20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders	
25	If the issue is contingent on *security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	

Appendix 3B New issue announcement

27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	
30	How do *security holders sell their entitlements <i>in full</i> through a broker?	
31	How do *security holders sell part of their entitlements through a broker and accept for the balance?	
32	How do *security holders dispose of their entitlements (except by sale through a broker)?	
33	⁺ Despatch date	

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(a)

securities

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

- If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
- If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories

1 - 1,000

1,001 - 5,000

5,001 - 10,000

10,001 - 100,000

100,001 and over

37 A copy of any trust deed for the additional *securities

Entities that have ticked box 34(b)

38	Number of securities for which †quotation is sought	
39	Class of *securities for which quotation is sought	

40	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?	-	
	If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now		
	Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another security, clearly identify that other security)		
		Number	+Class
42	Number and *class of all *securities quoted on ASX (including the securities in clause 38)		

⁺ See chapter 19 for defined terms.

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those +securities should not be granted +quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before *quotation of the *securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Date: 5 August 2019

Sign here:

(Company Secretary)

Stuart Usher

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for *eligible entities

Introduced 01/08/12

Part 1

Rule 7.1 – Issues exceeding 15% of capital Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Add the following:		
Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2	51,152,445	
Number of fully paid ordinary securities issued in that 12 month period with shareholder approval	226,250,000 391,267,878	
Number of partly paid ordinary securities that became fully paid in that 12 month period	130,197,956	
 Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
Subtract the number of fully paid ordinary securities cancelled during that 12 month period	-	
"A"	1,870,941,566	

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
Multiply "A" by 0.15	280,641,235	
Step 3: Calculate "C", the amount of phas already been used	lacement capacity under rule 7.1 that	
Insert number of equity securities issued or agreed to be issued in that 12 month period not counting those issued:	-	
• Under an exception in rule 7.2		
• Under rule 7.1A		
• With security holder approval under rule 7.1 or rule 7.4		
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
"C"	-	
Step 4: Subtract "C" from ["A" x "B"] to capacity under rule 7.1	to calculate remaining placement	
"A" x 0.15	280,641,235	
Note: number must be same as shown in Step 2		
Subtract "C" Note: number must be same as shown in Step 3	-	
Total ["A" x 0.15] – "C"	280,641,235	

[Note: this is the remaining placement capacity

under rule 7.1]

Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	-	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10	-	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used Insert number of equity securities issued or -		
agreed to be issued in that 12 month period under rule 7.1A		
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 		
"E"	_	

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D capacity under rule 7.1A	"] to calculate remaining placement
"A" x 0.10	-
Note: number must be same as shown in Step 2	
Subtract "E"	-
Note: number must be same as shown in Step 3	
Total ["A" x 0.10] – "E"	-
	Note: this is the remaining placement capacity under rule 7.1A

⁺ See chapter 19 for defined terms.